Phase II Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Recurrent or Metastatic Transitional Cell Carcinoma of the Urethelium.
Phase of Trial: Phase II
Latest Information Update: 18 Feb 2015
At a glance
- Drugs Vorinostat (Primary)
- Indications Bladder cancer; Urogenital cancer
- Focus Therapeutic Use
- 12 Feb 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 06 Aug 2012 Planned end date changed from 1 Dec 2010 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 01 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.